Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-Human CD47/MER6 Antibody (B6H12)

Catalog #:   FHG17620 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1, kappa
Applications: FCM
Accession: Q08722
Overview

Catalog No.

FHG17620

Species reactivity

Human

Host species

Mouse

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Target

Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q08722

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

B6H12

Data Image
  • Bioactivity
    Detects CD47/MER6 in indirect ELISAs.
  • Flow-cytometry
    Flow-cytometry using anti-human CD47 antibody.HeLa cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human CD47 antibody monoclonal antibody (Catalog # FHG17620 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-mouse antibody (Catalog # PMB96441) and cells analysed on a NovoCyte Flow Cytometer.
  • Flow-cytometry
    Flow-cytometry using anti-human CD47 antibody.K562 cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human CD47 antibody monoclonal antibody (Catalog # FHG17620 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-mouse antibody (Catalog # PMB96441) and cells analysed on a NovoCyte Flow Cytometer.
  • Flow-cytometry
    Flow-cytometry using anti-human CD47 antibody.Human peripheral blood monocytes were stained with an irrelevant antibody (Blue Histogram) or an anti-human CD47 antibody monoclonal antibody (Catalog # FHG17620 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-mouse antibody (Catalog # PMB96441) and cells analysed on a NovoCyte Flow Cytometer.
  • Flow-cytometry
    Flow-cytometry using anti-human CD47 antibody.Human peripheral blood lymphocytes were stained with an irrelevant antibody (Blue Histogram) or an anti-human CD47 antibody monoclonal antibody (Catalog # FHG17620 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-mouse antibody (Catalog # PMB96441) and cells analysed on a NovoCyte Flow Cytometer.
References

PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance., PMID:40512837

Nanoparticle-formulated mRNA encoding engineered multivalent SIRPα-Fc fusion proteins shows robust anti-cancer activity in preclinical models., PMID:40487351

Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer., PMID:40450521

Efferocytosis and its role in rheumatic diseases., PMID:40452369

Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions., PMID:40429716

CD99: A Key Regulator in Immune Response and Tumor Microenvironment., PMID:40427525

CDC34 suppresses macrophage phagocytic activity and predicts poor response to immune checkpoint inhibitor in cancers., PMID:40419082

The cytotoxic effect of quercetin-induced apoptosis on lung metastatic cells from giant cell tumor of bone., PMID:40418557

A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity., PMID:40408355

Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy., PMID:40402266

USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity., PMID:40379682

Tumor-derived exosomal CCT6A serves as a matchmaker introducing chemokines to tumor-associated macrophages in pancreatic ductal adenocarcinoma., PMID:40374617

CD47 expression in classic follicular lymphoma is associated with event-free survival., PMID:40374148

Immunotherapy of endometrial cancer via CD47 blockade-mediated macrophage phagocytosis., PMID:40371397

Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics Slows Disease Progression in Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Models., PMID:40361435

The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma., PMID:40358156

Dual targeting of ENPP3 and SIRPα with a bispecific antibody enhances macrophage-mediated immunity in renal cell carcinoma., PMID:40349459

Virtual Clinical Trial Reveals Significant Clinical Potential of Targeting Tumor-Associated Macrophages and Microglia to Treat Glioblastoma., PMID:40347051

Refolding of the recombinant IgV domain of CD47 from E. coli for NMR studies., PMID:40334763

Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT., PMID:40332470

Nanobody-Based PET Imaging of CD47 Expression in Thyroid Carcinoma., PMID:40326602

TSP-1-CD47-integrin α4β1 axis drives T cell infiltration and synovial inflammation in rheumatoid arthritis., PMID:40308591

CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation., PMID:40307254

Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells., PMID:40296909

N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycan., PMID:40289109

Engineered Bacterial Outer Membrane Vesicles Hitchhiking on Neutrophils for Antibody Drug Delivery to Enhance Postoperative Immune Checkpoint Therapy., PMID:40287972

Multi-Omics Analysis of the Immune Effect of the Engineered Exosome Drug Delivery System in Inducing Macrophage Apoptosis., PMID:40284489

CD47-blocking antibody confers metabolic benefits against obesity., PMID:40267910

CD47 regulates antigen modulation and red blood cell clearance following an incompatible transfusion., PMID:40255405

Inhibition of polymorphonuclear cells averts cytotoxicity against hypoimmune cells in xenotransplantation., PMID:40251154

Successful targeting of multidrug-resistant tumors with bispecific antibodies., PMID:40248904

Nanobody Engineered and Photosensitiser Loaded Bacterial Outer Membrane Vesicles Potentiate Antitumour Immunity and Immunotherapy., PMID:40240911

The "don't eat me" signal CD47 is associated with microglial phagocytosis defects and autism-like behaviors in 16p11.2 deletion mice., PMID:40238451

Molecular and Immunometabolic Landscape of Erythrophagocytosis-induced Ferroptosis., PMID:40231500

An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment., PMID:40207734

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis., PMID:40198272

High-Throughput Screening on Primary Tumor-Associated Microglia and Macrophages Identifies HDAC Inhibitors as Enhancers of Phagocytosis and Potent Partners for Immunotherapy in Glioblastoma., PMID:40196519

Generation and characterization of 7DC-DM1: a non-cleavable CD47-targeting antibody-drug conjugates with antitumor effects., PMID:40187444

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)., PMID:40175391

Dual blockade of GSTK1 and CD47 improves macrophage-mediated phagocytosis on cancer cells., PMID:40147800

A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors., PMID:40140179

Programmable engineered bacteria as sustained-releasing antibody factory in situ for enhancing tumor immune checkpoint therapy., PMID:40138400

Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy., PMID:40136470

Regulating islet stress responses through CD47 activation., PMID:40133488

CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery., PMID:40087866

Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile., PMID:40084615

Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy., PMID:40078999

Deciphering the IgG Idiotype Network Through Proteomic Analysis of Potential Targets in SARS-CoV-2-Induced Immune Responses., PMID:40077865

A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond., PMID:40069930

Blockade of TSP-1/CD47 signal axis promotes donor hematopoietic engraftment by improving SEC/MK niche function., PMID:40060904

Datasheet
$ 198
Product specifications
50 μg 198 100 μg 328

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human CD47/MER6 Antibody (B6H12) [FHG17620]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only